medigraphic.com
ISSN 1405-8790 (Impreso)

2011, Número 4

<< Anterior Siguiente >>

Rev Mex Med Fis Rehab 2011; 23 (4)


Lactobacillus acidophilus, bifidus bacterium en pacientes con lesión medular e intestino neurogénico en Rehabilitación

Castellanos-Valencia A, Berumen-Amor E, Martín-Ortiz G

Idioma: Español
Referencias bibliográficas: 42
Paginas: 123-128
Archivo PDF: 67.27 Kb.


RESUMEN

Objetivo: Demostrar la efectividad del bio-gel simbiótico sinérgico con Lactobacillus acidophilus, bifidus bacterium e inulina de agave Webber tequilana azul en pacientes con lesión medular que presentan intestino neurogénico. Diseño: Ensayo clínico cegado, controlado, no aleatorizado. Método: Pacientes con intestino neurogénico en el Centro de Rehabilitación Infantil, previa firma de consentimiento informado; se les administró alternadamente simbiótico y azúcar, aplicando cuestionario referente al hábito de evacuaciones, medidas antropométricas, dieta, síntomas intestinales, antes y cuatro semanas postratamiento. Resultados: 64 pacientes incluidos, 31 con simbiótico, 33 con azúcar, rango de edad 1-22 años, 59% masculinos, cualquier nivel de lesión medular. Los promedios de número de evacuaciones por semana pretratramiento fueron: 3.3/2.5, postratamiento: 10.7/10.3 con simbiótico y azúcar respectivamente, la consistencia con escala de Bristol previo fue 1.7/1.5 y posterior 3.4/3.8. Hubo diferencias significativas en sangrado intestinal (p = 0.04), distención abdominal (p = 0.01), disminución de eventos diarreicos (p ‹ 0.001), dolor abdominal (p = 0.002) favoreciendo al simbiótico sinérgico. Sin reacciones adversas. Conclusiones: Clínicamente en tránsito intestinal, el simbiótico beneficia igual que el azúcar, pero en sangrado, diarrea, distención y dolor abdominal actúa reparando el ecosistema y motilidad colónica. El uso de simbiótico sinérgico puede reducir la utilización crónica de laxantes para control de intestino neurogénico en pacientes con lesión medular.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mcdonald JW, Sadowsky CL. Spinal-cord Injury Seminar. Lancet 2002; 359: 417-25.

  2. Botto LD, Moore CA, Khoury MJ, Erickson JD. Neural tube defects. Review. The New Eng J Med 1999; 341(20): 1509-19.

  3. Au KS, Tran PX, Tsai CC et al. Characteristics of a spina bifida population including North American Caucasian and Hispanic individuals. Birth Defects Res A Clin Mol Teratol 2008; 82: 692-700.

  4. Valdés-Hernández J, Canún-Serrano S, Reyes-Pablo AE, Navarrete-Hernández E. Mortalidad por defectos en el cierre del tubo neural en menores de 5 años de edad en México de 1998 a 2006. Salud Publica Mex 2010; 52: 341-349.

  5. The National Spinal Cord Injury Statistical Center. University of Alabama at Birmingham, 2009. Annual Statistical Report. 2010.

  6. Krogh K, Nielsen J, Djurhuus JC, Mosdal C, Sabroe S, Laurberg S. Colorectal function in patients with spinal cord lesions. Dis Colon Rectum 1997; 40: 1233-1239.

  7. Salvioli B, DeGiorgio R, Stanghellini V, Barbara G, Menarini M, Corinaldesi R, Bazzocchi G. Rectosigmoid compliance and visceral perception in spinal cord injury patients. Gastroenterology 2006; 130(S2): A-795.

  8. Bazzocchi G, Salvioli B, Bonatti E, Poletti E, Marani E, Stanghellini V, Menarini M. Relationship between ASIA score and anorectal visceral sensory testing in patients with SCI. J Spinal Cord Med 2006; 29: 338-339.

  9. Bornstein JC, Costa M, Grider JR. Enteric motor and interneuronal circuits controllino motility. Neurogastroenterol Motil 2004; 16(S1): 34-8.

  10. Bazzocchi G, Schuijt C, Pederzini R, Menarini M. Bowel dysfunction in spinal cord injury patients: patho-physiology and management. Pelviperineology 2007; 26: 84-87.

  11. Stephen AM, Cummings JH. The microbial contribution to human fecal mass. J Med Microbiol 1980; 13(1): 45-56.

  12. Cosman BC, Stone JM, Perkash I. Gastrointestinal complications of chronic spinal cord injury. J Am Paraplegia Soc 1991; 14: 175-81.

  13. Stone JM, Nino-Murcia M, Wolfe VA, Perkash I. Chronic gastrointestinal problems in spinal cord injury patients: a prospective analysis. Am J Gastroenterol 1990; 85: 1114-9.

  14. Aisen ML, Brownn W, Rubin M. Electrophysiologic changes in lumbar spinal cord after cervical cord injury. Neurology 1992; 42: 623-6.

  15. American College of Chest Physicians/Society of Critical Care. Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-75.

  16. Khalif IL, Quigley EMM, Konovitch EA, Maximova ID. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liv Dis 2005; 37: 838-849.

  17. Christensen P, Bazzocchi G, Coggrave M, Abel R, Hultling C, Krogh K, Media S, Laurberg S. Treatment of fecal incontinence and constipation in patients with spinal cord injury: a prospective, randomized, controlled, multicenter trial of transanal irrigation vs conservative bowel management. Gastroenterology 2006; 131: 738-47.

  18. Altermann E, Russell WM, Azcarate-Peril MA et al. Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. Proc Natl Acad Sci USA 2005; 102(11): 3906-12.

  19. Zareie M, Johnson-Henry K, Jury J, Yang PC, Ngan BY, McKay DM, Soderholm JD, Perdue MH, Sherman PM. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 2006; 55(11): 1553-60.

  20. Klarin B, Johansson ML, Molin G, Larsson A, Jeppsson B. Adhesion of the probiotic bacterium. Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomized open trial. Critical Care 2005; 9: R285-R293.

  21. Vargas-Vorackova F. Evaluación de gel biodigestivo simbiótico Ventro, en la recuperación de la microbiota intestinal en voluntarios sanos bajo esquema antimicrobiano. 2008 (GAS-151-07-09-1).

  22. Borriello SP, Hammes WP, Holzapfel W et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003; 36: 775-80.

  23. Roberfroid MB. Inulin-type fructans: functional food ingredients. J Nutr 2007; 137(S11): 2493-2502.

  24. Haas U, Geng V, Evers GC, Knecht H. Bowel management in patients with spinal cord injury: A multicentre study of the German speaking society of paraplegia (DMGP). Spinal Cord 2005; 43(12): 724-30.

  25. Consortium for Spinal Cord Medicine. Neurogenic bowel management in adults with spinal cord injury: Clinical practice guidelines for health-care professionals. Washington, DC: Paralyzed Veterans of America, 1998.

  27. Coggrave M, Norton C, Wilson-Barnett J. Management of neurogenic bowel dysfunction in the community after spinal cord injury: a postal survey in the United Kingdom. Spinal Cord 2009; 47(4): 323-30.

  28. Glickman S, Kamm M. Bowel dysfunction in spinal cord injury patients. Lancet 1996; 347(9016): 1651-3.

  29. Xing JH, Soffer EE. Adverse effects of laxatives. Diseases of the Colon and Rectum 2001; 44(8): 1201-1209.

  30. Müller-Lissner SA. Adverse effects of laxatives: fact and fiction. Pharmacology 1993; 47(Suppl 1): 138-45.

  31. Watanabe T, Nakaya N, Kurashima K et al. Constipation, laxative use and risk of colorectal cancer: the Miyagi cohort study. Eur J Cancer 2004; 40: 2109-15.

  32. Cameron KJ, Nyulasi IB, Collier GR, Brown DJ. Assessment of the effect of increased dietary fibre intake in patients with spinal cord injury. Spinal Cord 1996; 34(5): 277-83C.

  33. Buchholz AC, McGillivray CF, Pencharz PB. Physical activity levels are low in free-living adults with chronic paraplegia. Obes Res 2003; 11: 563-70.

  34. Jenab M, Thompson LU. The influence of flaxseed and lignans on colon carcinogenesis and b-glucuronidase activity. Carcinogenesis 1996; 17(6): 1343-8.

  35. Kurpad AV, Shetty PS. Effects of antimicrobial therapy on fecal bulking. Gut 1986; 27: 55-8.

  36. Jernberg S, Lofmark C, Edlund, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 2010; 156: 3216-23.

  37. Hviid A, Svanström H, Frisch M. Antibiotics use and inflammatory bowel disease in childhood. Gut 2011; 60: 49-54.

  38. Van Houte J, Gibbons RJ. Studies of the cultivable flora of normal human feces. Antonie van Leeuwenhoek 1966; 32: 212-22.

  39. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR. A randomized controlled trial of a probiotic, VSL #3, on gut transit and symptoms in diarrhoea–predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 2003; 17: 895-904.

  40. Bazzocchi G, Gionchetti P, Almerigi PF, Amadini C, Campieri M. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Digestive & Liver Diseases 2002; 34(S2): 48-53.

  41. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. American Journal of Gastroenterology 2000; 95: 1231-8.

  42. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-51.




2020     |     www.medigraphic.com